Table 2.
Expression of CD43s by AML and MDS
| Patient ID | WHO 2008 classification | AT1413 (MFI FI) |
|---|---|---|
| AML with recurrent genetic abnormalities | ||
| BL-039 | AML with t(8;21) | 3.2 |
| BL-045 | AML with t(8;21) | 3.9 |
| BL-065 | AML with t(8;21) | 15.8 |
| BL-066 | AML with t(8;21) | 2.9 |
| BL-069 | AML with t(8;21) | 7.1 |
| BL-025 | AML with inv(16) | 21.3 |
| BL-038 | AML with inv (16) | 4.2 |
| BL-043 | AML with inv (16) | 5.4 |
| BL-070 | AML with inv (16) | 5.1 |
| BL-037 | APL; T(15;17)(q22;q12) | 5.0 |
| BL-031 | AML with t(6;9) | 6.3 |
| BL-068 | AML with t(6;9) | 4.0 |
| BL-010 | AML with mutated NPM1 | 9.2 |
| BL-051 | AML with mutated NPM1 | 15.9 |
| BL-061 | AML with mutated NPM1 | 5.5 |
| Pt 78 | AML with mutated NPM1 | 2.2 |
| BL-057 | EVI1 17p del | 9.6 |
| BL-059 | RUNX1+ FLT3/ITD+ | 12.4 |
| Acute leukemia of ambiguous lineage | ||
| BL-060 | Acute undifferentiated leukemia | 12.9 |
| Therapy-related myeloid neoplasms | ||
| BL-047 | t-AML | 7.5 |
| BL-074 | t-AML | 3.8 |
| BL-028 | t-AML | 2.2 |
| AML, not otherwise specified | ||
| Pt 77 | AML without maturation | 13.8 |
| Pt 86 | AML without maturation | 12.9 |
| BL-064 | AML without maturation | 2.9 |
| Pt 80 | AML with minimal differentiation | 48.9 |
| BL-007 | AML with minimal differentiation | 21.3 |
| BL-009 | AML with minimal differentiation | 10.9 |
| BL-030 | AML with minimal differentiation | 29.0 |
| BL-063 | AML with minimal differentiation | 8.4 |
| Pt 87 | AML with maturation | 38.6 |
| BL-071 | AML with maturation | 2.3 |
| BL-046 | Acute myelomonocytic leukemia | 3.3 |
| BL-053 | Acute myelomonocytic leukemia | 4.2 |
| BL-034* | Acute monoblastic/monocytic leukemia | 2.5 |
| Pt 101† | Acute monoblastic/monocytic leukemia | 6.4 |
| AML with myelodysplasia-related changes | ||
| BL-014 | History of MDS | 3.1 |
| BL-055 | History of MDS | 2.4 |
| BL-052 | Multilineage dysplasia | 22.4 |
| BL-054 | Multilineage dysplasia | 6.4 |
| Myelodysplastic syndromes | ||
| BL-032 | RCUD | 2.2 |
| BL-011 | RCMD | 5.7 |
| Pt 81 | RAEB-II | 3.3 |
| BL-022 | RAEB-II | 9.0 |
| BL-033 | RAEB-II | 3.4 |
| BL-042 | RAEB-II | 2.0 |
| BL-058 | RAEB-II | 1.9 |
| BL-062 | RAEB-I | 7.6 |
MFI fold increase (FI) for AT1413 binding to CD45dim leukemic blasts isolated from newly diagnosed AML and patients with MDS. Depicted is MFI for AT1413 divided by the MFI of the negative control antibody (AT1002).
*Patient deferred further treatment and cytogenetic and molecular analyses were not performed.
†From this patient AT1413 was retrieved.